Vertex Pharmaceuticals Inc. (VRTX) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Vertex Pharmaceuticals is a global biotechnology company focused on cystic fibrosis (CF), sickle cell disease (SCD), beta thalassemia, and acute pain. The company operates in a single segment: pharmaceuticals.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Total Revenues | $3,333.9M | $2,964.7M | $6,320.8M | $5,734.9M |
| Net Income | $1,099.8M | $1,032.9M | $2,131.2M | $1,679.2M |
| Diluted EPS | $4.31 | $3.99 | $8.33 | $6.48 |
| Operating Cash Flow (YTD) | $2,553.5M | $1,892.0M | - | - |
| Cash & Marketable Securities | $13,641.5M | - | - | - |
| Working Capital | $8,605.8M | - | - | - |
| Effective Tax Rate (YTD) | 19.4% | 16.6% | - | - |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 12% in Q2 2026 compared to Q2 2025, driven by strong performance in CF therapies and growth in non-CF products.
- Product Performance:
- ALYFTREK: Revenues surged 266% QoQ and 374% YoY to $573.6M (Q2) and $998.0M (YTD), driven by new country reimbursements and pediatric uptake.
- CASGEVY: Revenues grew 151% YoY to $76.4M (Q2) following FDA approval for children as young as two.
- JOURNAVX: Revenues increased 313% YoY to $49.6M (Q2) due to expanded Medicare Part D coverage.
- TRIKAFTA/KAFTRIO: Revenues declined 2% YoY to $2,497.2M (Q2) as patients transition to newer therapies.
- Expenses: Selling, general, and administrative (SG&A) expenses rose 37% YoY to $582.2M due to commercial investments for JOURNAVX and the anticipated launch of povetacicept. R&D expenses remained relatively flat at $993.8M.
- Impairment: No intangible asset impairment charges were recorded in 2026, compared to a $379.0M charge in Q1 2025 related to the VX-264 program.
Guidance, Outlook, and Risks
- Strategic Acquisition: On July 6, 2026, Vertex announced an agreement to acquire Crinetics Pharmaceuticals for approximately $10.0 billion ($85.00/share). The deal is expected to close in Q3 2026 and will be funded by cash and a new $4.5 billion term loan.
- Pipeline Milestones:
- Povetacicept: FDA PDUFA date for accelerated approval in IgA nephropathy is November 30, 2026.
- ALYFTREK: Global regulatory submissions initiated for children aged 2-5.
- Suzetrigine: Health Canada accepted the new drug submission for acute pain; Phase 3 enrollment for diabetic peripheral neuropathy expected to complete by end of 2026.
- Legal Contingency: Royalty Pharma plc initiated arbitration alleging the royalty burden on ALYFTREK is ~8% rather than Vertex's stated 4%. Vertex intends to vigorously defend its position; no material loss contingency has been accrued.
- Capital Structure: Vertex entered a new $500M revolving credit facility and a $4.5B term loan in July 2026 to support the Crinetics acquisition. As of June 30, 2026, $2.6 billion remained available under the share repurchase program.
Investor Verification Checklist
- Verify the closing conditions and regulatory approval status of the Crinetics Pharmaceuticals acquisition.
- Monitor the outcome of the arbitration with Royalty Pharma regarding ALYFTREK royalty rates, which could impact future margins.
- Track the FDA decision on povetacicept (PDUFA date: Nov 30, 2026) for the IgA nephropathy indication.
- Assess the integration plan and commercial performance of CASGEVY in the newly approved pediatric population.
- Review the impact of the new $4.5 billion term loan on future interest expenses and leverage ratios.